A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes

• Published in: Nature communications 2021-09, Vol.12 (1), p.5503-8, Article 5503
• Main Authors: Harrison, Stephen A., Gunn, Nadege, Neff, Guy W., Kohli, Anita, Liu, Liping, Flyer, Abbey, Goldkind, Lawrence, Di Bisceglie, Adrian M.
• Format: Article
• Language: English
• Subjects: 692/163/2743/137; 692/4020/4021/1607/2751; Adiposity - drug effects; Adult; Adverse events; Aged; Berberine; Berberine - adverse effects; Berberine - pharmacology; Berberine - therapeutic use; Clinical trials; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diarrhea; Enzymes; Fatty liver; Female; Glycated Hemoglobin - analysis; Health services; Humanities and Social Sciences; Humans; Lipids; Liver; Liver - drug effects; Liver - metabolism; Liver - pathology; Liver diseases; Magnetic resonance imaging; Male; Middle Aged; multidisciplinary; Non-alcoholic Fatty Liver Disease - complications; Non-alcoholic Fatty Liver Disease - drug therapy; Patients; Placebos; Proof of Concept Study; Proton density (concentration); Reduction; Science; Science (multidisciplinary); Ursodeoxycholic acid; Weight loss
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-021-25701-5

Non-alcoholic steatohepatitis is frequently associated with diabetes and may cause progressive liver disease. Current treatment options are limited. Here we report on a prospective, randomised, double-blind, placebo-controlled trial of two doses of HTD1801 (berberine ursodeoxycholate, an ionic salt of berberine and ursodeoxycholic acid), versus placebo that was conducted in 100 subjects with fatty liver disease and diabetes (NCT03656744). Treatment was for 18 weeks with a primary endpoint of reduction in liver fat content measured by magnetic resonance imaging proton density fat fraction. Key secondary endpoints included improvement in glycemic control, liver-associated enzymes and safety. The pre-specified primary endpoint was met. Thus, subjects receiving 1000 mg twice a day of berberine ursodeoxycholate had significantly greater reduction in liver fat content than in placebo recipients (mean absolute decrease −4.8% vs. −2.0% ( p  = 0.011). Compared to placebo, subjects receiving this dose also experienced significant improvement in glycemic control as well as reductions in liver-associated enzymes and significant weight loss. Diarrhea and abdominal discomfort were the most frequently reported adverse events. We conclude that berberine ursodeoxycholate has a broad spectrum of metabolic activity in patients with presumed NASH and diabetes. It is relatively well tolerated and merits further development as a treatment for NASH with diabetes. Berberine ursodeoxycholate has been studied for its serum lipid and lipoprotein lowering effects. Here the authors report an 18-week phase 2, randomised, double-blind, placebo-controlled clinical trial that tested the effect of berberine ursodeoxycholate in patients with fatty liver disease and diabetes, and showed that the group taking the higher dose of the drug had reduced liver fat content.